A redox switch in angiotensinogen modulates angiotensin release

Blood pressure is critically controlled by angiotensins, which are vasopressor peptides specifically released by the enzyme renin from the tail of angiotensinogen—a non-inhibitory member of the serpin family of protease inhibitors. Although angiotensinogen has long been regarded as a passive substrate, the crystal structures solved here to 2.1 Å resolution show that the angiotensin cleavage site is inaccessibly buried in its amino-terminal tail. The conformational rearrangement that makes this site accessible for proteolysis is revealed in our 4.4 Å structure of the complex of human angiotensinogen with renin. The co-ordinated changes involved are seen to be critically linked by a conserved but labile disulphide bridge. Here we show that the reduced unbridged form of angiotensinogen is present in the circulation in a near 40:60 ratio with the oxidized sulphydryl-bridged form, which preferentially interacts with receptor-bound renin. We propose that this redox-responsive transition of angiotensinogen to a form that will more effectively release angiotensin at a cellular level contributes to the modulation of blood pressure. Specifically, we demonstrate the oxidative switch of angiotensinogen to its more active sulphydryl-bridged form in the maternal circulation in pre-eclampsia—the hypertensive crisis of pregnancy that threatens the health and survival of both mother and child.

[1]  D. Harrison,et al.  Oxidative stress and hypertension. , 2007, Journal of the American Society of Hypertension : JASH.

[2]  R. Carrell,et al.  Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. , 1989, Biochemistry.

[3]  K. Moore,et al.  Persistent S-Nitrosation of Complex I and Other Mitochondrial Membrane Proteins by S-Nitrosothiols but Not Nitric Oxide or Peroxynitrite , 2006, Journal of Biological Chemistry.

[4]  P. Stein,et al.  Ovalbumin and angiotensinogen lack serpin S-R conformational change. , 1989, The Biochemical journal.

[5]  U. Jakob,et al.  Thiol-based redox switches in eukaryotic proteins. , 2009, Antioxidants & redox signaling.

[6]  L. Myatt Review: Reactive oxygen and nitrogen species and functional adaptation of the placenta. , 2010, Placenta.

[7]  C. Hubel,et al.  Oxidative Stress in the Pathogenesis of Preeclampsia (44447) , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[8]  F. Fyhrquist,et al.  Renin‐angiotensin system revisited , 2008, Journal of internal medicine.

[9]  F. Pipkin,et al.  Reduced Selenium Concentrations and Glutathione Peroxidase Activity in Preeclamptic Pregnancies , 2008, Hypertension.

[10]  C. Weydert,et al.  Chronic Tempol Prevents Hypertension, Proteinuria, and Poor Feto-Placental Outcomes in BPH/5 Mouse Model of Preeclampsia , 2008, Hypertension.

[11]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[12]  Santiago Lamas,et al.  Nitrosylation The Prototypic Redox-Based Signaling Mechanism , 2001, Cell.

[13]  John Quackenbush,et al.  A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. , 1997, The Journal of clinical investigation.

[14]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[15]  J. Lalouel,et al.  A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system , 1995, The Journal of Biological Chemistry.

[16]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[17]  K. Takahashi,et al.  Two peaks in pH dependence of renin-angiotensinogen reaction. , 1998, Bioscience, biotechnology, and biochemistry.

[18]  B. Ustundag,et al.  Oxidant-Antioxidant System Changes Relative to Placental-Umbilical Pathology in Patients with Preeclampsia , 2005, Hypertension in pregnancy.

[19]  H. Kobori,et al.  The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease , 2007, Pharmacological Reviews.

[20]  H. S. Kim,et al.  Genetic control of blood pressure and the angiotensinogen locus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Carrell,et al.  Angiotensinogen cleavage by renin: importance of a structurally constrained N‐terminus , 1998, FEBS letters.

[22]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[23]  C. Wilcox Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[24]  James J. Walker,et al.  Pre-eclampsia , 2000, The Lancet.

[25]  C. Sigmund,et al.  Genetic basis of hypertension: revisiting angiotensinogen. , 2006, Hypertension.

[26]  T. Blundell,et al.  X-ray analysis at 2.0 A resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen. , 1994, Journal of molecular biology.

[27]  E. Jauniaux,et al.  Placental Oxidative Stress: From Miscarriage to Preeclampsia , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.

[28]  X. Jeunemaître,et al.  Role of Cysteine Residues in Human Angiotensinogen , 1998, The Journal of Biological Chemistry.

[29]  J. Granger,et al.  Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats. , 2008, American journal of hypertension.

[30]  N. Powell,et al.  Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. , 2005, Bioorganic & medicinal chemistry letters.